# EDGAR Filing Document

**Accession Number:** 0001844417
**File Stem:** 0001213900-25-092471
**Filing Date:** 2025-9
**Character Count:** 5334
**Document Hash:** ca6c57b29b26c342831603e319d8b103
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-092471.hdr.sgml**: 20250926

**ACCESSION NUMBER**: 0001213900-25-092471

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250922

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20250926

**DATE AS OF CHANGE**: 20250926

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Estrella Immunopharma, Inc.
- **CENTRAL INDEX KEY:** 0001844417
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 861314502
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40608
- **FILM NUMBER:** 251351532

**BUSINESS ADDRESS:**
- **STREET 1:** 5858 HORTON STREET, SUITE 370
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
- **BUSINESS PHONE:** (510) 318-9098

**MAIL ADDRESS:**
- **STREET 1:** 5858 HORTON STREET, SUITE 370
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TradeUP Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210204

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **September 22, 2025**

**Estrella Immunopharma, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40608** | **86-1314502** |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer |
| of incorporation) |  | Identification Number) |

---

---

| | |
|:---|:---|
| **5858 Horton Street, Suite 370**<br> **Emeryville, California** | **94608** |
| (Address of principal executive offices) | (Zip Code) |

---

**(510) 318-9098**

**(**Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act.

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | ESLA | The Nasdaq Stock Market LLC |
| Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 | ESLAW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On September 22, 2025, the Board of Directors (the "Board") of Estrella Immunopharma, Inc. (the "Company") appointed Jia Dengyao to serve as a member of the Board, effective immediately. As of the date of this Current Report on Form 8-K, Mr. Jia has not been appointed and is not expected to be appointed to any committees of the Board.

In connection with the appointment of Mr. Jia, the Company entered into an indemnification agreement with Mr. Jia on substantially similar terms as the indemnification agreements the Company has previously entered into with its other non-employee directors. This indemnification agreement requires the Company to indemnify Mr. Jia for certain reasonable expenses, including attorneys' fees and retainers, court costs, and witness and expert costs, incurred by Mr. Jia in any action or proceeding, and any appeal thereof, arising out of his service as a director of the Company or any other company to which Mr. Jia provides services at the request of the Company.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Estrella Immunopharma, Inc.** | **Estrella Immunopharma, Inc.** |
|  | By: | /s/ Cheng Liu |
|  | Name: | Cheng Liu |
|  | Title: | Chief Executive Officer |
| Date: September 26, 2025 |  |  |

---